DUBLIN, September 23, 2022 /PRNewswire/ — The “Global Markets for Insulin Drugs and Delivery Technologies” report has been added to from ResearchAndMarkets.com offer.
The current report will provide an in-depth review of the insulin drugs market and delivery technologies. This report analyzes Insulin Drugs and Delivery Technologies market trends with data from 2021, estimates from 2022, projections of compound annual growth rates to 2027 (2022 forecast period -2027) and regional insulin drug and delivery technology markets.
This report will highlight the current and future business potential of Insulin Drugs and Delivery Technologies along with a detailed analysis of the competitive environment. Regulatory scenarios, drivers, restraints and opportunities will be covered in the current report. The report also covers market projections for 2026 and the market share of major market players.
Insulin medications and delivery technologies are used to manage type 1 and type 2 diabetes. Rapid insulin delivery devices such as smart pens help diabetes patients optimize control of blood sugar and minimize the risk of associated health problems. Advanced insulin delivery devices provide better patient compliance.
Traditional insulin syringes and pumps are being replaced by reusable and disposable insulin pens due to the latter’s portability, greater dosing accuracy, built-in memory, larger dosages and ease of administration. use. There have been no major breakthroughs in traditional syringes and pumps.
Major manufacturers of insulin delivery devices include Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG. The main manufacturers of modern insulin and human insulin are Sanofi, Eli Lilly, Novo Nordisk, Boehringer Ingelheim International GmbH, Biocon and Viatris Inc.
The growth of the market is attributed to factors such as increasing incidence of diabetes and new drug and insulin delivery technologies. The global insulin drugs and delivery technologies market is segmented by device type, insulin type, and region.
In this report, the market has been segmented on the basis of device type, insulin type, and geographical region. Types of devices include syringes, insulin pens, insulin pumps, smart pens, and others. Types of insulin include long-acting, rapid-acting, premixed, intermediate-acting, and short-acting insulins.
Geographic regions covered include North America, Europe, Asia Pacific and the rest of the world (RoW). Individual countries covered include the United States, GermanyGreat Britain, Italy, France, Japan, China and India.
Descriptive company profiles of major manufacturers of modern insulin and insulin delivery devices including Sanofi, Eli Lilly, Novo Nordisk, Medtronic, F. Hoffmann-La Roche (Roche) Ltd., Becton Dickinson (BD), Ypsomed AG and B. Braun Melsungen AG
The report includes
24 data tables and 31 additional tables
An up-to-date review of the global insulin drug markets and delivery technologies
Global market trend analyses, with historic market revenue (sales data) for 2020 and 2021, estimates for 2022, and compound annual growth rate (CAGR) projections to 2027
Highlights of the current status of drug and insulin delivery industry structure, new technology updates and issues related to insulin pens and insulin syringes, current research activities and scenarios regulation and pricing
Estimation of the actual market size and market forecast for insulin drugs and delivery technologies, and analysis of the corresponding market share by device type, insulin type and geographical region
Updated information on major M&A deals, partnerships, collaborations and other strategic alliances within the insulin drug and delivery technology industry
Analysis of market opportunities with a holistic review of Porter’s five forces analysis model considering both micro and macro environmental factors prevalent in the market
Identification of key stakeholders and analysis of the competitive landscape based on recent developments and industry revenue
Main topics covered:
Chapter 1 Introduction
1.1 Overview of insulin
1.2 Overview of Diabetes
1.2.1 Disease symptoms and risk factors
1.2.2 Epidemiology and economic burden
1.3 Aims and objectives of the study
1.4 Reasons for doing this study
1.5 What’s new in this update?
1.6 Scope of the report
1.7 Sources of information
1.9 Geographical distribution
1.10 Analyst Skills
1.11 Custom Search
1.12 Related Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market Dynamics
3.1 Market Drivers
3.1.1 Increasing prevalence of diabetes
3.1.2 Smart Insulin Drug Delivery Technologies
3.1.3 Painless insulin drug delivery technologies
3.2 Market constraints
3.2.1 Product recalls
3.3 Market Opportunities
3.3.1 Inorganic strategies among market players
Chapter 4 Market Overview
4.1 Market Overview
4.2 Current Market Trends
4.2.1 Recent Product Introductions
4.2.2 Recent strategic alliances
4.3 Future prospects
Chapter 5 Regulatory Landscape and Reimbursement Scenario
5.1 Regulatory landscape
5.1.1 US medical device regulations
5.1.2 US drug regulations
5.1.3 European regulations for medical devices
5.1.4 European drug regulations
5.1.5 Asia-Pacific regulation for medical devices
5.2 Reimbursement scenario
5.2.1 Overview of Pricing and Reimbursement
5.2.2 Pricing and reimbursement of medical devices
5.2.3 Pricing and reimbursement of pharmaceutical products
5.3.1 Insurance for diabetic emergencies
Chapter 6 Impact of Covid-19 on the Market
6.2 Covid-19 crisis
6.2.1 Insulin Drugs and Delivery Technologies Market Impact
6.2.2 Covid-19 measures
Chapter 7 Market Breakdown by Device Type
7.1 Insulin delivery technologies
7.1.2 Insulin pens
7.1.3 Insulin pumps
7.1.4 Smart Pens
Chapter 8 Market Breakdown by Insulin Type
8.1.1 Structure of insulin
8.1.2 Insulin biosynthesis
8.1.3 Types of insulin
Chapter 9 Market Breakdown by Region
9.1.1 North America
9.1.3 Asia Pacific
9.1.4 Rest of the world
Chapter 10 Market Opportunity Analysis
10.1 Porter’s Five Forces Analysis
10.1.1 Threat of new entrants
10.1.2 Threat of Substitutes
10.1.3 Bargaining Power of Suppliers
10.1.4 Bargaining power of buyers
10.1.5 Degree of competition
Chapter 11 Competitive Landscape
Chapter 12 Business Profiles
12.1 Large companies
B. Braun Melsungen AG
Becton, Dickinson and Co.
Boehringer Ingelheim International GmbH
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Novo Nordisk A/S
Ypsomed Holding SA
Emperra GmbH eHealth Technologies
Nanopass Technologies Ltd.
Nipro Medical Corp.
Owen Mumford Ltd.
Tandem Diabetes Care Inc.
For more information on this report, visit https://www.researchandmarkets.com/r/qw0qyx
Research and Markets
For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716
Show original content:https://www.prnewswire.com/news-releases/global-insulin-drug-and-delivery-technology-market-analysis-report-2022-rising-prevalence-of-diabetes-smart-insulin-drug-delivery- technologies–painless-insulin-drug-delivery-technologies-301631950.html
SOURCE Research and Markets